Small Bowel Adenocarcinoma

• Autores: Thomas Aparicio, Aziz Zaanan, Florence Mary, Pauline Afchain, Sylvain Manfredi, Thomas Ronald Jeffry Evans
• Localización: Gastroenterology clinics of North America, ISSN 0889-8553, Vol. 45, Nº. 3, 2016 (Ejemplar dedicado a: Gastrointestinal Neoplasia), págs. 447-457
• Idioma: inglés
• Enlaces
  • Texto Completo Ejemplar
• Resumen

  • Small bowel adenocarcinomas (SBAs) are rare tumors, but their incidence is increasing. The most common primary location is the duodenum. Even though SBAs are more often sporadic, some diseases are risk factors. Early diagnosis of small bowel adenocarcinoma remains difficult, despite significant radiologic and endoscopic progress. After R0 surgical resection, the main prognostic factor is lymph node invasion. An international randomized trial (BALLAD [Benefit of Adjuvant Chemotherapy For Small Bowel Adenocarcinoma] study) will evaluate the benefit of adjuvant chemotherapy. For metastatic disease, retrospectives studies suggest that platinum-based chemotherapy is the most effective treatment. Phase II studies are ongoing to evaluate targeted therapy in metastatic SBA.